Immunome to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness Wire • 09/03/25
Immunome Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 08/06/25
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?Zacks Investment Research • 06/12/25
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a BetZacks Investment Research • 05/26/25
Immunome Reports First Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 05/12/25
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to TradeZacks Investment Research • 05/08/25
Immunome Reports Full Year 2024 Financial Results and Provides Business UpdateBusiness Wire • 03/19/25
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADCBusiness Wire • 03/10/25
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 01/31/25
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/13/25